Prix
Questions fréquentes
Quelle est la capitalisation boursière de GeoVax Labs ?
Quel est le bénéfice par action (BPA) de GeoVax Labs ?
Quelles sont les évaluations des analystes et le prix cible de l'action GeoVax Labs ?
Quel est le chiffre d'affaires de GeoVax Labs sur les douze derniers mois ?
Quel est l'EBITDA de GeoVax Labs ?
Quel est le flux de trésorerie disponible de GeoVax Labs ?
Quel est le bêta à 5 ans de l'action GeoVax Labs ?
Combien d'employés compte GeoVax Labs, et à quel secteur d'activité appartient-elle ?
Quel est le flottant des actions de GeoVax Labs ?
Finances
Capitalisation boursière
25,48 M $USbêta sur 5 ans
3,25BPA (TTM)
-9,207 $USFree Float
9,39 MRecettes (TTM)
3,09 M $USEBITDA (TTM)
-24,40 M $USCash-flow disponible (TTM)
-27,24 M $USCotation
Notes des analystes
L'objectif de prix est de 72,00 $US et l'action est analysée par 3 analystes.
Acheter
3
Hold
0
Vendre
0
Informations
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
17
Biotechnology & Drugs
Soins de santé
Identifiant
ISIN
Ticker primaire